GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Generate Biomedicines, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$12.56+0.47 (+3.89%)
Close on Oct 19, 2026
- Market cap
- $1.61B
- P/E (TTM)
- –
- Dividend yield
- –
About Generate Biomedicines
Pharmaceutical Preparations, SIC 2834
Generate Biomedicines, Inc. is listed on Nasdaq under the ticker GENB, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Generate Biomedicines, Inc.
- Headquarters
- Somerville, MA
- Address
- 101 South Street, Suite 900 02143
- Phone
- (888) 469-0055
- Website
- generatebiomedicines.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- GENB
- Exchange
- Nasdaq
- IPO date
- Feb 27, 2026
- Shares outstanding
- 128M, Jul 29, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2100782
- CUSIP
- 370920100
- ISIN
- US3709201004
- EIN
- 83-1630228
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michael Nally | Chief Executive Officer, Director | 2,889,154 |
| Gevorg Grigoryan | Chief Technology Officer | 659,973 |
| Beth Grous | Chief People Officer | 300 |
| Laurie Anne Lee | Chief Medical Officer | – |
| Jason Silvers | President & CFO | 1,500 |
| Sean Martin | Chief Legal Officer & GC | – |
| Aarif Khakoo | Chief Scientific Officer | – |
| Frances Arnold | Director | 463,944 |
| Paul Gray Parker | Director | – |
| Nancy A. Simonian | Director | – |
| Jane L. Mendillo | Director | 1,500 |
| Marsha Fanucci | Director | – |
| Rupert Vessey | Director | – |
| Noubar Afeyan | Director | – |
| Stephane Bancel | Director | 1,184,989 |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 27, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 24, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |